메뉴 건너뛰기




Volumn 27, Issue 9, 2013, Pages 1891-1901

The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia

Author keywords

acute myeloid leukemia; CBL; core binding factor; FLT3; KIT; RAS

Indexed keywords

CBL PROTEIN; CD135 ANTIGEN; CORE BINDING FACTOR; STEM CELL FACTOR RECEPTOR;

EID: 84883742457     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.186     Document Type: Article
Times cited : (126)

References (58)
  • 1
    • 79952092487 scopus 로고    scopus 로고
    • Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications
    • Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011; 29: 475-486.
    • (2011) J Clin Oncol , vol.29 , pp. 475-486
    • Marcucci, G.1    Haferlach, T.2    Dohner, H.3
  • 2
    • 84879352656 scopus 로고    scopus 로고
    • How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
    • Patel JP, Levine RL. How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? Hematology Am Soc Hematol Educ Program 2012; 2012: 28-34.
    • (2012) Hematology Am Soc Hematol Educ Program , vol.2012 , pp. 28-34
    • Patel, J.P.1    Levine, R.L.2
  • 3
    • 77955914238 scopus 로고    scopus 로고
    • Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
    • Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
    • (2010) Blood , vol.116 , pp. 354-365
    • Grimwade, D.1    Hills, R.K.2    Moorman, A.V.3    Walker, H.4    Chatters, S.5    Goldstone, A.H.6
  • 4
    • 79952099282 scopus 로고    scopus 로고
    • Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial
    • Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29: 369-377.
    • (2011) J Clin Oncol , vol.29 , pp. 369-377
    • Burnett, A.K.1    Hills, R.K.2    Milligan, D.3    Kjeldsen, L.4    Kell, J.5    Russell, N.H.6
  • 5
    • 55749083387 scopus 로고    scopus 로고
    • Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia
    • Mrozek K, Marcucci G, Paschka P, Bloomfield CD. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 2008; 20: 711-718.
    • (2008) Curr Opin Oncol , vol.20 , pp. 711-718
    • Mrozek, K.1    Marcucci, G.2    Paschka, P.3    Bloomfield, C.D.4
  • 7
    • 23744498520 scopus 로고    scopus 로고
    • Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22)
    • DOI 10.1038/sj.leu.2403803
    • Nanri T, Matsuno N, Kawakita T, Suzushima H, Kawano F, Mitsuya H et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 2005; 19: 1361-1366. (Pubitemid 41136329)
    • (2005) Leukemia , vol.19 , Issue.8 , pp. 1361-1366
    • Nanri, T.1    Matsuno, N.2    Kawakita, T.3    Suzushima, H.4    Kawano, F.5    Mitsuya, H.6    Asou, N.7
  • 8
    • 33646432204 scopus 로고    scopus 로고
    • Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study
    • Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006; 107: 3463-3468.
    • (2006) Blood , vol.107 , pp. 3463-3468
    • Cairoli, R.1    Beghini, A.2    Grillo, G.3    Nadali, G.4    Elice, F.5    Ripamonti, C.B.6
  • 10
    • 33344465478 scopus 로고    scopus 로고
    • KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
    • DOI 10.1182/blood-2005-04-1466
    • Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006; 107: 1791-1799. (Pubitemid 43289355)
    • (2006) Blood , vol.107 , Issue.5 , pp. 1791-1799
    • Schnittger, S.1    Kohl, T.M.2    Haferlach, T.3    Kern, W.4    Hiddemann, W.5    Spiekermann, K.6    Schoch, C.7
  • 11
    • 80052097088 scopus 로고    scopus 로고
    • Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia
    • Park SH, Chi HS, Min SK, Park BG, Jang S, Park CJ. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 2011; 35: 1376-1383.
    • (2011) Leuk Res , vol.35 , pp. 1376-1383
    • Park, S.H.1    Chi, H.S.2    Min, S.K.3    Park, B.G.4    Jang, S.5    Park, C.J.6
  • 13
    • 84872056078 scopus 로고    scopus 로고
    • Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): A study of the German-Austrian AML Study Group (AMLSG)
    • Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). Blood 2013; 121: 170-177.
    • (2013) Blood , vol.121 , pp. 170-177
    • Paschka, P.1    Du, J.2    Schlenk, R.F.3    Gaidzik, V.I.4    Bullinger, L.5    Corbacioglu, A.6
  • 14
    • 39149092043 scopus 로고    scopus 로고
    • Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples
    • Shih LY, Liang DC, Huang CF, Chang YT, Lai CL, Lin TH et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia 2008; 22: 303-307.
    • (2008) Leukemia , vol.22 , pp. 303-307
    • Shih, L.Y.1    Liang, D.C.2    Huang, C.F.3    Chang, Y.T.4    Lai, C.L.5    Lin, T.H.6
  • 15
    • 77950612017 scopus 로고    scopus 로고
    • Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
    • Pollard JA, Alonzo TA, Gerbing RB, Ho PA, Zeng R, Ravindranath Y et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010; 115: 2372-2379.
    • (2010) Blood , vol.115 , pp. 2372-2379
    • Pollard, J.A.1    Alonzo, T.A.2    Gerbing, R.B.3    Ho, P.A.4    Zeng, R.5    Ravindranath, Y.6
  • 18
    • 34548029756 scopus 로고    scopus 로고
    • FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
    • DOI 10.1182/blood-2006-04-015826
    • Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007; 110: 1262-1270. (Pubitemid 47281424)
    • (2007) Blood , vol.110 , Issue.4 , pp. 1262-1270
    • Mead, A.J.1    Linch, D.C.2    Hills, R.K.3    Wheatley, K.4    Burnett, A.K.5    Gale, R.E.6
  • 19
    • 41949090673 scopus 로고    scopus 로고
    • The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
    • Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776-2784.
    • (2008) Blood , vol.111 , pp. 2776-2784
    • Gale, R.E.1    Green, C.2    Allen, C.3    Mead, A.J.4    Burnett, A.K.5    Hills, R.K.6
  • 21
    • 84860914670 scopus 로고    scopus 로고
    • The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype
    • Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T et al. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. Blood 2012; 119: 4383-4386.
    • (2012) Blood , vol.119 , pp. 4383-4386
    • Schneider, F.1    Hoster, E.2    Unterhalt, M.3    Schneider, S.4    Dufour, A.5    Benthaus, T.6
  • 22
    • 84878344487 scopus 로고    scopus 로고
    • Favorable outcome of patients with acute myeloid leukemia harboring a lowallelic burden FLT3-ITD mutation and concomitant NPM1 mutation: Relevance to post-remission therapy
    • Pratcorona M, Brunet S, Nomdedeu J, Ribera JM, Tormo M, Duarte R et al. Favorable outcome of patients with acute myeloid leukemia harboring a lowallelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 2013; 121(14): 2734-2738.
    • (2013) Blood , vol.121 , Issue.14 , pp. 2734-2738
    • Pratcorona, M.1    Brunet, S.2    Nomdedeu, J.3    Ribera, J.M.4    Tormo, M.5    Duarte, R.6
  • 23
    • 0842328518 scopus 로고    scopus 로고
    • Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16)
    • Valk PJ, Bowen DT, Frew ME, Goodeve AC, Lowenberg B, Reilly JT. Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16). Haematologica 2004; 89: 106. (Pubitemid 38165863)
    • (2004) Haematologica , vol.89 , Issue.1 , pp. 106
    • Valk, P.J.M.1    Bowen, D.T.2    Frew, M.E.3    Goodeve, A.C.4    Lowenberg, B.5    Reilly, J.T.6
  • 24
    • 65249132999 scopus 로고    scopus 로고
    • CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes
    • Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res 2009; 15: 2238-2247.
    • (2009) Clin Cancer Res , vol.15 , pp. 2238-2247
    • Reindl, C.1    Quentmeier, H.2    Petropoulos, K.3    Greif, P.A.4    Benthaus, T.5    Argiropoulos, B.6
  • 26
    • 77952420655 scopus 로고    scopus 로고
    • AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions
    • Haferlach C, Dicker F, Kohlmann A, Schindela S, Weiss T, Kern W et al. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia 2010; 24: 1065-1069.
    • (2010) Leukemia , vol.24 , pp. 1065-1069
    • Haferlach, C.1    Dicker, F.2    Kohlmann, A.3    Schindela, S.4    Weiss, T.5    Kern, W.6
  • 27
    • 54349105660 scopus 로고    scopus 로고
    • Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias
    • Abbas S, Rotmans G, Lowenberg B, Valk PJ. Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias. Haematologica 2008; 93: 1595-1597.
    • (2008) Haematologica , vol.93 , pp. 1595-1597
    • Abbas, S.1    Rotmans, G.2    Lowenberg, B.3    Valk, P.J.4
  • 28
    • 0030895252 scopus 로고    scopus 로고
    • Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the medical research council's 10th AML trial (MRC AML10)
    • Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997; 89: 2311-2318. (Pubitemid 27143277)
    • (1997) Blood , vol.89 , Issue.7 , pp. 2311-2318
    • Hann, I.M.1    Stevens, R.F.2    Goldstone, A.H.3    Rees, J.K.H.4    Wheatley, K.5    Gray, R.G.6    Burnett, A.K.7
  • 29
    • 77449155696 scopus 로고    scopus 로고
    • Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: Results of the MRC AML12 trial
    • Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol 2010; 28: 586-595.
    • (2010) J Clin Oncol , vol.28 , pp. 586-595
    • Burnett, A.K.1    Hills, R.K.2    Milligan, D.W.3    Goldstone, A.H.4    Prentice, A.G.5    McMullin, M.F.6
  • 30
    • 84867297401 scopus 로고    scopus 로고
    • Minimal residual disease monitoring by RT-qPCR in core-binding factor AML allows risk-stratification and predicts relapse: Results of the UK MRC AML-15 trial
    • Liu Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by RT-qPCR in core-binding factor AML allows risk-stratification and predicts relapse: results of the UK MRC AML-15 trial. Blood 2012; 120: 2826-2835.
    • (2012) Blood , vol.120 , pp. 2826-2835
    • Liu Yin, J.A.1    O'Brien, M.A.2    Hills, R.K.3    Daly, S.B.4    Wheatley, K.5    Burnett, A.K.6
  • 32
    • 79952286086 scopus 로고    scopus 로고
    • C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice
    • Wang YY, Zhao LJ, Wu CF, Liu P, Shi L, Liang Y et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2011; 108: 2450-2455.
    • (2011) Proc Natl Acad Sci USA , vol.108 , pp. 2450-2455
    • Wang, Y.Y.1    Zhao, L.J.2    Wu, C.F.3    Liu, P.4    Shi, L.5    Liang, Y.6
  • 33
    • 84863418375 scopus 로고    scopus 로고
    • KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice
    • Zhao L, Melenhorst JJ, Alemu L, Kirby M, Anderson S, Kench M et al. KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice. Blood 2012; 119: 1511-1521.
    • (2012) Blood , vol.119 , pp. 1511-1521
    • Zhao, L.1    Melenhorst, J.J.2    Alemu, L.3    Kirby, M.4    Anderson, S.5    Kench, M.6
  • 34
    • 70349256226 scopus 로고    scopus 로고
    • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes
    • Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
    • (2009) Blood , vol.114 , pp. 937-951
    • Vardiman, J.W.1    Thiele, J.2    Arber, D.A.3    Brunning, R.D.4    Borowitz, M.J.5    Porwit, A.6
  • 36
    • 38349185874 scopus 로고    scopus 로고
    • HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: Collaborative study between the German AML Intergroup and CIBMTR
    • Schlenk RF, Pasquini MC, Perez WS, Zhang MJ, Krauter J, Antin JH et al. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant 2008; 14: 187-196.
    • (2008) Biol Blood Marrow Transplant , vol.14 , pp. 187-196
    • Schlenk, R.F.1    Pasquini, M.C.2    Perez, W.S.3    Zhang, M.J.4    Krauter, J.5    Antin, J.H.6
  • 37
    • 79953124101 scopus 로고    scopus 로고
    • Blood consult: Acute myeloid leukemia and the t(8;21)(q22;22)
    • Park JH, Hedvat CV, Tallman MS. Blood consult: acute myeloid leukemia and the t(8;21)(q22;22). Blood 2011; 117: 2775-2777.
    • (2011) Blood , vol.117 , pp. 2775-2777
    • Park, J.H.1    Hedvat, C.V.2    Tallman, M.S.3
  • 39
    • 47649131141 scopus 로고    scopus 로고
    • Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease
    • Mead AJ, Gale RE, Hills RK, Gupta M, Young BD, Burnett AK et al. Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood 2008; 112: 444-445.
    • (2008) Blood , vol.112 , pp. 444-445
    • Mead, A.J.1    Gale, R.E.2    Hills, R.K.3    Gupta, M.4    Young, B.D.5    Burnett, A.K.6
  • 40
    • 84877930402 scopus 로고    scopus 로고
    • Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
    • Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013; 121: 2213-2223.
    • (2013) Blood , vol.121 , pp. 2213-2223
    • Jourdan, E.1    Boissel, N.2    Chevret, S.3    Delabesse, E.4    Renneville, A.5    Cornillet, P.6
  • 41
    • 17044435979 scopus 로고    scopus 로고
    • KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor
    • Kohl TM, Schnittger S, Ellwart JW, Hiddemann W, Spiekermann K. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 2005; 105: 3319-3321.
    • (2005) Blood , vol.105 , pp. 3319-3321
    • Kohl, T.M.1    Schnittger, S.2    Ellwart, J.W.3    Hiddemann, W.4    Spiekermann, K.5
  • 42
    • 28444437728 scopus 로고    scopus 로고
    • Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate
    • DOI 10.1182/blood-2005-02-0583
    • Cammenga J, Horn S, Bergholz U, Sommer G, Besmer P, Fiedler W et al. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood 2005; 106: 3958-3961. (Pubitemid 41739038)
    • (2005) Blood , vol.106 , Issue.12 , pp. 3958-3961
    • Cammenga, J.1    Horn, S.2    Bergholz, U.3    Sommer, G.4    Besmer, P.5    Fiedler, W.6    Stocking, C.7
  • 43
    • 77956497048 scopus 로고    scopus 로고
    • Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations
    • Yang Y, Letard S, Borge L, Chaix A, Hanssens K, Lopez S et al. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood 2010; 116: 1114-1123.
    • (2010) Blood , vol.116 , pp. 1114-1123
    • Yang, Y.1    Letard, S.2    Borge, L.3    Chaix, A.4    Hanssens, K.5    Lopez, S.6
  • 44
    • 79959763366 scopus 로고    scopus 로고
    • Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816
    • Kim SY, Kang JJ, Lee HH, Kim B, Kim CG, Park TK et al. Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816. Biochem Biophys Res Commun 2011; 410: 224-228.
    • (2011) Biochem Biophys Res Commun , vol.410 , pp. 224-228
    • Kim, S.Y.1    Kang, J.J.2    Lee, H.H.3    Kim, B.4    Kim, C.G.5    Park, T.K.6
  • 45
    • 84863183137 scopus 로고    scopus 로고
    • Distinct classes of c-Kitactivating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia
    • Nick HJ, Kim HG, Chang CW, Harris KW, Reddy V, Klug CA. Distinct classes of c-Kitactivating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia. Blood 2012; 119: 1522-1531.
    • (2012) Blood , vol.119 , pp. 1522-1531
    • Nick, H.J.1    Kim, H.G.2    Chang, C.W.3    Harris, K.W.4    Reddy, V.5    Klug, C.A.6
  • 46
    • 31544459272 scopus 로고    scopus 로고
    • Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
    • DOI 10.1158/0008-5472.CAN-05-2050
    • Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473-481. (Pubitemid 43166056)
    • (2006) Cancer Research , vol.66 , Issue.1 , pp. 473-481
    • Schittenhelm, M.M.1    Shiraga, S.2    Schroeder, A.3    Corbin, A.S.4    Griffith, D.5    Lee, F.Y.6    Bokemeyer, C.7    Deininger, M.W.N.8    Druker, B.J.9    Heinrich, M.C.10
  • 47
    • 0036785393 scopus 로고    scopus 로고
    • Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: Implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors
    • Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002; 100: 2393-2398.
    • (2002) Blood , vol.100 , pp. 2393-2398
    • Kottaridis, P.D.1    Gale, R.E.2    Langabeer, S.E.3    Frew, M.E.4    Bowen, D.T.5    Linch, D.C.6
  • 48
    • 0036786289 scopus 로고    scopus 로고
    • Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: A comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
    • Shih LY, Huang CF, Wu JH, Lin TL, Dunn P, Wang PN et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002; 100: 2387-2392.
    • (2002) Blood , vol.100 , pp. 2387-2392
    • Shih, L.Y.1    Huang, C.F.2    Wu, J.H.3    Lin, T.L.4    Dunn, P.5    Wang, P.N.6
  • 49
    • 84862776906 scopus 로고    scopus 로고
    • Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
    • Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510.
    • (2012) Nature , vol.481 , pp. 506-510
    • Ding, L.1    Ley, T.J.2    Larson, D.E.3    Miller, C.A.4    Koboldt, D.C.5    Welch, J.S.6
  • 50
    • 34547621066 scopus 로고    scopus 로고
    • Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice
    • DOI 10.1158/0008-5472.CAN-07-0778
    • Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice. Cancer Res 2007; 67: 7139-7146. (Pubitemid 47206541)
    • (2007) Cancer Research , vol.67 , Issue.15 , pp. 7139-7146
    • Parikh, C.1    Subrahmanyam, R.2    Ren, R.3
  • 51
    • 79951815187 scopus 로고    scopus 로고
    • N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene
    • Chou FS, Wunderlich M, Griesinger A, Mulloy JC. N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene. Blood 2011; 117: 2237-2240.
    • (2011) Blood , vol.117 , pp. 2237-2240
    • Chou, F.S.1    Wunderlich, M.2    Griesinger, A.3    Mulloy, J.C.4
  • 53
    • 33646575624 scopus 로고    scopus 로고
    • Implications of NRAS mutations in AML: A study of 2502 patients
    • DOI 10.1182/blood-2005-08-3522
    • Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107: 3847-3853. (Pubitemid 43726786)
    • (2006) Blood , vol.107 , Issue.10 , pp. 3847-3853
    • Bacher, U.1    Haferlach, T.2    Schoch, C.3    Kern, W.4    Schnittger, S.5
  • 55
    • 77957965853 scopus 로고    scopus 로고
    • Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling
    • Rathinam C, Thien CB, Flavell RA, Langdon WY. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling. Cancer Cell 2010; 18: 341-352.
    • (2010) Cancer Cell , vol.18 , pp. 341-352
    • Rathinam, C.1    Thien, C.B.2    Flavell, R.A.3    Langdon, W.Y.4
  • 57
    • 24944464648 scopus 로고    scopus 로고
    • Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study
    • Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 5705-5717.
    • (2005) J Clin Oncol , vol.23 , pp. 5705-5717
    • Marcucci, G.1    Mrozek, K.2    Ruppert, A.S.3    Maharry, K.4    Kolitz, J.E.5    Moore, J.O.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.